Ritonavir
Brand names: Norvir
Ritonavir is an HIV protease inhibitor used almost exclusively at low dose as a pharmacokinetic booster to enhance levels of other protease inhibitors and some antivirals.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It potently inhibits the cytochrome P450 3A4 enzyme, slowing metabolism of co-administered drugs and thereby boosting their plasma concentrations.
Prescribing in practice
- As a strong CYP3A4 inhibitor, ritonavir causes extensive and potentially serious drug interactions; screen all concomitant medicines before and during treatment.
- Several commonly used drugs are contraindicated owing to risk of toxic accumulation, so check interactions meticulously.
- It is used predominantly as a booster rather than for its own antiviral effect.
Monitoring
Monitor for drug-interaction effects, liver function and lipids during therapy.
Counselling the patient
- Always tell any prescriber or pharmacist that you take ritonavir, as it interacts with many medicines.
- Do not start new medicines, including over-the-counter or herbal products, without checking first.
- Report any new or unusual side effects, which may indicate an interaction.
Evidence & guidelines
Low-dose ritonavir boosting is a well-established pharmacokinetic strategy in HIV and other antiviral therapy.
Reference: BHIVA; UK Liverpool HIV interactions; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023